APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immune Checkpoint Blockers

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Immune Checkpoint Blockers Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025180 pages

Choose your research edition.

Industry ResearchImmune Checkpoint Blockers Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Checkpoint Blockers Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Immune Checkpoint Blockers Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Checkpoint Blockers Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Checkpoint Blockers Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Immune Checkpoint Blockers market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Immune Checkpoint Blockers is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immune Checkpoint Blockers is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immune Checkpoint Blockers is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Immune Checkpoint Blockers is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Immune Checkpoint Blockers include Sanofi, Merck, Roche, AbbVie, AstraZeneca and Bristol Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Immune Checkpoint Blockers market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immune Checkpoint Blockers and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immune Checkpoint Blockers sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Immune Checkpoint Blockers market size, projected growth trends, production technologies, key applications, and end-use industries.

Immune Checkpoint Blockers Segment by Company

Sanofi

Merck

Roche

AbbVie

AstraZeneca

Bristol Myers Squibb

Immune Checkpoint Blockers Segment by Type

Anti-PD-L1 Drug

Anti-PD-1 Drug

CTLA4

Immune Checkpoint Blockers Segment by Application

Blood Cancers

BreastCancer

Prostate Cancer

Colorectal Cancer

Melanoma

Lung Cancer

Immune Checkpoint Blockers Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Checkpoint Blockers market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Checkpoint Blockers and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Checkpoint Blockers.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Immune Checkpoint Blockers market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Immune Checkpoint Blockers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Immune Checkpoint Blockers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Immune Checkpoint Blockers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Immune Checkpoint Blockers Industry Trends Table 2. Immune Checkpoint Blockers Industry Drivers Table 3. Immune Checkpoint Blockers Industry Opportunities and Challenges Table 4. Immune Checkpoint Blockers Industry Restraints Table 5. Global Immune Checkpoint Blockers Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Immune Checkpoint Blockers Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Immune Checkpoint Blockers Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Immune Checkpoint Blockers Sales Market Share by Manufacturers Table 9. Global Immune Checkpoint Blockers Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Immune Checkpoint Blockers Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Immune Checkpoint Blockers Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Immune Checkpoint Blockers Manufacturers, Product Type & Application Table 13. Global Immune Checkpoint Blockers Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Immune Checkpoint Blockers by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anti-PD-L1 Drug Table 17. Major Manufacturers of Anti-PD-1 Drug Table 18. Major Manufacturers of CTLA4 Table 19. Global Immune Checkpoint Blockers Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Immune Checkpoint Blockers Sales by Type (2021-2026) & (k units) Table 21. Global Immune Checkpoint Blockers Sales by Type (2027-2032) & (k units) Table 22. Global Immune Checkpoint Blockers Sales Market Share by Type (2021-2026) Table 23. Global Immune Checkpoint Blockers Sales Market Share by Type (2027-2032) Table 24. Global Immune Checkpoint Blockers Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Immune Checkpoint Blockers Revenue by Type (2021-2026) & (k units) Table 26. Global Immune Checkpoint Blockers Revenue by Type (2027-2032) & (k units) Table 27. Global Immune Checkpoint Blockers Revenue Market Share by Type (2021-2026) Table 28. Global Immune Checkpoint Blockers Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Blood Cancers Table 30. Major Manufacturers of BreastCancer Table 31. Major Manufacturers of Prostate Cancer Table 32. Major Manufacturers of Colorectal Cancer Table 33. Major Manufacturers of Melanoma Table 34. Major Manufacturers of Lung Cancer Table 35. Global Immune Checkpoint Blockers Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Immune Checkpoint Blockers Sales by Application (2021-2026) & (k units) Table 37. Global Immune Checkpoint Blockers Sales by Application (2027-2032) & (k units) Table 38. Global Immune Checkpoint Blockers Sales Market Share by Application (2021-2026) Table 39. Global Immune Checkpoint Blockers Sales Market Share by Application (2027-2032) Table 40. Global Immune Checkpoint Blockers Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Immune Checkpoint Blockers Revenue by Application (2021-2026) & (k units) Table 42. Global Immune Checkpoint Blockers Revenue by Application (2027-2032) & (k units) Table 43. Global Immune Checkpoint Blockers Revenue Market Share by Application (2021-2026) Table 44. Global Immune Checkpoint Blockers Revenue Market Share by Application (2027-2032) Table 45. Global Immune Checkpoint Blockers Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Immune Checkpoint Blockers Sales by Region (2021-2026) & (k units) Table 47. Global Immune Checkpoint Blockers Sales Market Share by Region (2021-2026) Table 48. Global Immune Checkpoint Blockers Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Immune Checkpoint Blockers Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Immune Checkpoint Blockers Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Immune Checkpoint Blockers Sales by Country (2021-2026) & (k units) Table 52. North America Immune Checkpoint Blockers Sales by Country (2027-2032) & (k units) Table 53. Europe Immune Checkpoint Blockers Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Immune Checkpoint Blockers Sales by Country (2021-2026) & (k units) Table 55. Europe Immune Checkpoint Blockers Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Immune Checkpoint Blockers Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Immune Checkpoint Blockers Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Immune Checkpoint Blockers Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Immune Checkpoint Blockers Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Immune Checkpoint Blockers Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Immune Checkpoint Blockers Sales by Country (2027-2032) & (k units) Table 62. Global Immune Checkpoint Blockers Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Immune Checkpoint Blockers Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Immune Checkpoint Blockers Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Immune Checkpoint Blockers Revenue Market Share by Region (2021-2026) Table 66. Global Immune Checkpoint Blockers Revenue Market Share by Region (2027-2032) Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi Immune Checkpoint Blockers Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Sanofi Immune Checkpoint Blockers Product Portfolio Table 71. Sanofi Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Immune Checkpoint Blockers Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Merck Immune Checkpoint Blockers Product Portfolio Table 76. Merck Recent Development Table 77. Roche Company Information Table 78. Roche Business Overview Table 79. Roche Immune Checkpoint Blockers Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Roche Immune Checkpoint Blockers Product Portfolio Table 81. Roche Recent Development Table 82. AbbVie Company Information Table 83. AbbVie Business Overview Table 84. AbbVie Immune Checkpoint Blockers Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. AbbVie Immune Checkpoint Blockers Product Portfolio Table 86. AbbVie Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Immune Checkpoint Blockers Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AstraZeneca Immune Checkpoint Blockers Product Portfolio Table 91. AstraZeneca Recent Development Table 92. Bristol Myers Squibb Company Information Table 93. Bristol Myers Squibb Business Overview Table 94. Bristol Myers Squibb Immune Checkpoint Blockers Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Bristol Myers Squibb Immune Checkpoint Blockers Product Portfolio Table 96. Bristol Myers Squibb Recent Development Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Immune Checkpoint Blockers Distributors List Table 100. Immune Checkpoint Blockers Customers List Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Immune Checkpoint Blockers Product Image Figure 2. Global Immune Checkpoint Blockers Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Checkpoint Blockers Market Size (2021-2032) & (US$ Million) Figure 4. Global Immune Checkpoint Blockers Sales (2021-2032) & (k units) Figure 5. Global Immune Checkpoint Blockers Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Immune Checkpoint Blockers Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anti-PD-L1 Drug Image Figure 9. Anti-PD-1 Drug Image Figure 10. CTLA4 Image Figure 11. Global Immune Checkpoint Blockers Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Immune Checkpoint Blockers Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Immune Checkpoint Blockers Sales Market Share by Type (2021-2032) Figure 14. Global Immune Checkpoint Blockers Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Immune Checkpoint Blockers Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Immune Checkpoint Blockers Revenue Market Share by Type (2021-2032) Figure 17. Blood Cancers Image Figure 18. BreastCancer Image Figure 19. Prostate Cancer Image Figure 20. Colorectal Cancer Image Figure 21. Melanoma Image Figure 22. Lung Cancer Image Figure 23. Global Immune Checkpoint Blockers Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Immune Checkpoint Blockers Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Immune Checkpoint Blockers Sales Market Share by Application (2021-2032) Figure 26. Global Immune Checkpoint Blockers Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Immune Checkpoint Blockers Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Immune Checkpoint Blockers Revenue Market Share by Application (2021-2032) Figure 29. North America Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Immune Checkpoint Blockers Sales Market Share by Country (2021-2032) Figure 31. U.S. Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Immune Checkpoint Blockers Sales Market Share by Country (2021-2032) Figure 36. Germany Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Immune Checkpoint Blockers Sales Market Share by Country (2021-2032) Figure 43. China Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Immune Checkpoint Blockers Sales Market Share by Country (2021-2032) Figure 51. Brazil Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Immune Checkpoint Blockers Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Immune Checkpoint Blockers Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Immune Checkpoint Blockers Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Immune Checkpoint Blockers Revenue (2021-2032) & (US$ Million) Figure 62. North America Immune Checkpoint Blockers Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Immune Checkpoint Blockers Revenue (2021-2032) & (US$ Million) Figure 64. Europe Immune Checkpoint Blockers Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Immune Checkpoint Blockers Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Immune Checkpoint Blockers Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Immune Checkpoint Blockers Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Immune Checkpoint Blockers Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Immune Checkpoint Blockers Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Immune Checkpoint Blockers Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-PD-L1 Drug
  • Anti-PD-1 Drug
  • CTLA4
Applications
  • Blood Cancers
  • BreastCancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Lung Cancer
Companies covered
  • Sanofi
  • Merck
  • Roche
  • AbbVie
  • AstraZeneca
  • Bristol Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Immune Checkpoint Blockers Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Immune Checkpoint Blockers Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Immune Checkpoint Blockers Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Immune Checkpoint Blockers Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Immune Checkpoint Blockers Market Dynamics
  1. 2.1 Immune Checkpoint Blockers Industry Trends
  2. 2.2 Immune Checkpoint Blockers Industry Drivers
  3. 2.3 Immune Checkpoint Blockers Industry Opportunities and Challenges
  4. 2.4 Immune Checkpoint Blockers Industry Restraints
3 Immune Checkpoint Blockers Market by Manufacturers
  1. 3.1 Global Immune Checkpoint Blockers Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Immune Checkpoint Blockers Sales by Manufacturers (2021-2026)
  3. 3.3 Global Immune Checkpoint Blockers Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Immune Checkpoint Blockers Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Immune Checkpoint Blockers Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Immune Checkpoint Blockers Manufacturers, Product Type & Application
  7. 3.7 Global Immune Checkpoint Blockers Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Immune Checkpoint Blockers Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Immune Checkpoint Blockers Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Immune Checkpoint Blockers Tier 1, Tier 2, and Tier 3
4 Immune Checkpoint Blockers Market by Type
  1. 4.1 Immune Checkpoint Blockers Type Introduction
  2. 4.1.1 Anti-PD-L1 Drug
  3. 4.1.2 Anti-PD-1 Drug
  4. 4.1.3 CTLA4
  5. 4.2 Global Immune Checkpoint Blockers Sales by Type
  6. 4.2.1 Global Immune Checkpoint Blockers Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Immune Checkpoint Blockers Sales by Type (2021-2032)
  8. 4.2.3 Global Immune Checkpoint Blockers Sales Market Share by Type (2021-2032)
  9. 4.3 Global Immune Checkpoint Blockers Revenue by Type
  10. 4.3.1 Global Immune Checkpoint Blockers Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Immune Checkpoint Blockers Revenue by Type (2021-2032)
  12. 4.3.3 Global Immune Checkpoint Blockers Revenue Market Share by Type (2021-2032)
5 Immune Checkpoint Blockers Market by Application
  1. 5.1 Immune Checkpoint Blockers Application Introduction
  2. 5.1.1 Blood Cancers
  3. 5.1.2 BreastCancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Colorectal Cancer
  6. 5.1.5 Melanoma
  7. 5.1.6 Lung Cancer
  8. 5.2 Global Immune Checkpoint Blockers Sales by Application
  9. 5.2.1 Global Immune Checkpoint Blockers Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Immune Checkpoint Blockers Sales by Application (2021-2032)
  11. 5.2.3 Global Immune Checkpoint Blockers Sales Market Share by Application (2021-2032)
  12. 5.3 Global Immune Checkpoint Blockers Revenue by Application
  13. 5.3.1 Global Immune Checkpoint Blockers Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Immune Checkpoint Blockers Revenue by Application (2021-2032)
  15. 5.3.3 Global Immune Checkpoint Blockers Revenue Market Share by Application (2021-2032)
6 Global Immune Checkpoint Blockers Sales by Region
  1. 6.1 Global Immune Checkpoint Blockers Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immune Checkpoint Blockers Sales by Region (2021-2032)
  3. 6.2.1 Global Immune Checkpoint Blockers Sales by Region (2021-2026)
  4. 6.2.2 Global Immune Checkpoint Blockers Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Immune Checkpoint Blockers Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Immune Checkpoint Blockers Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Immune Checkpoint Blockers Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Immune Checkpoint Blockers Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Immune Checkpoint Blockers Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Immune Checkpoint Blockers Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Immune Checkpoint Blockers Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Immune Checkpoint Blockers Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Immune Checkpoint Blockers Revenue by Region
  1. 7.1 Global Immune Checkpoint Blockers Revenue by Region
  2. 7.1.1 Global Immune Checkpoint Blockers Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Immune Checkpoint Blockers Revenue by Region (2021-2026)
  4. 7.1.3 Global Immune Checkpoint Blockers Revenue by Region (2027-2032)
  5. 7.1.4 Global Immune Checkpoint Blockers Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Immune Checkpoint Blockers Revenue (2021-2032)
  8. 7.2.2 North America Immune Checkpoint Blockers Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Immune Checkpoint Blockers Revenue (2021-2032)
  11. 7.3.2 Europe Immune Checkpoint Blockers Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Immune Checkpoint Blockers Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Immune Checkpoint Blockers Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Immune Checkpoint Blockers Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Immune Checkpoint Blockers Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Immune Checkpoint Blockers Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Immune Checkpoint Blockers Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Immune Checkpoint Blockers Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Immune Checkpoint Blockers Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Immune Checkpoint Blockers Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Immune Checkpoint Blockers Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Immune Checkpoint Blockers Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Immune Checkpoint Blockers Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Immune Checkpoint Blockers Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Immune Checkpoint Blockers Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Bristol Myers Squibb
  32. 8.6.1 Bristol Myers Squibb Company Information
  33. 8.6.2 Bristol Myers Squibb Business Overview
  34. 8.6.3 Bristol Myers Squibb Immune Checkpoint Blockers Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bristol Myers Squibb Immune Checkpoint Blockers Product Portfolio
  36. 8.6.5 Bristol Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Immune Checkpoint Blockers Value Chain Analysis
  2. 9.1.1 Immune Checkpoint Blockers Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Immune Checkpoint Blockers Production Mode & Process
  6. 9.2 Immune Checkpoint Blockers Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Immune Checkpoint Blockers Distributors
  9. 9.2.3 Immune Checkpoint Blockers Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst